EUVIMEDEUVIMED entdecken
Crossref

Drug-eluting bead transarterial chemoembolization treatment of liver-dominant metastatic leiomyosarcoma

Jonathan Henning, Shree Venkat, Premsai Kumar, Ghassan El-Haddad, Andrew Brohl, Mauricio Ribeiro, Rahul Mhaskar, Arash Naghavi, Mihaela Druta, Bela Kis

Abdominal Radiology · 2026

DOI: 10.1007/s00261-025-05356-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Abdominal Radiology, 2026. Verfasst von Jonathan Henning und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida, Tampa, USA. Hauptthemen laut MEDLINE: Leiomyosarcoma, Liver Neoplasms, Chemoembolization, Therapeutic, Doxorubicin. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To analyze the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) treatment of unresectable metastatic hepatic leiomyosarcoma. METHODS: Medical records and imaging of patients with metastatic leiomyosarcoma to the liver who underwent doxorubicin DEB-TACE from December 2014 to September 2024 were retrospectively reviewed to evaluate survival and clinical and biochemical toxicities. RESULTS: The study included 29 patients (9 males, 20 females; average age 60.1 ± 12.7 years). Twenty-three patients (79.3%) had bilobar and 6 patients (20.7%) had unilobar disease. Twenty patients (69%) had extrahepatic metastases at the time of the first DEB-TACE. Twenty-five patients (86%) received systemic therapies before DEB-TACE, and 5 of these patients had hepatic metastasectomy. The median overall survival (OS) from the first DEB-TACE was 16.3 months (95% CI 2.2; 30.4), from diagnosis of liver metastasis was 35.8 months (95% CI 21.0; 50.6), and from primary diagnosis was 67.5 months (95% CI 49.2; 85.8). At 3 months post-DEB-TACE, the objective response was 79% (23 out of 29 patients), and the disease control rate was 96% (28 out of 29 patients), evaluated by mRECIST. The median liver progression-free survival from the first DEB-TACE was 7.8 months (95% CI 4.5; 11.2). There were two grade 3 clinical toxicities, four grade 3 laboratory toxicities, and 20 grade 1 or 2 laboratory toxicities. There was no 30-day mortality and no mortality related to DEB-TACE. CONCLUSION: DEB-TACE is safe and effective treatment in patients with liver-dominant unresectable leiomyosarcoma with minimal side effects. The 35.8 months median OS from diagnosis of liver metastasis is very promising in this patient population with unresectable, chemotherapy-refractory disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeiomyosarcomaLiver NeoplasmsChemoembolization, TherapeuticDoxorubicinAntibiotics, AntineoplasticHumansFemaleMiddle AgedMaleRetrospective StudiesTreatment OutcomeAged

Stichwörter der Autor:innen

LeiomyosarcomaLiver-directed therapySarcomaTransarterial chemoembolization

Substanzen

DoxorubicinAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • University of South Florida, Tampa, USA.
  • Moffitt Cancer Center, Tampa, USA.
  • Moffitt Cancer Center, Tampa, USA. bela.kis@moffitt.org.

Zitieren

APA

Henning, J., Venkat, S., Kumar, P., El-Haddad, G., Brohl, A., Ribeiro, M., Mhaskar, R., Naghavi, A., Druta, M., & Kis, B. (2026). Drug-eluting bead transarterial chemoembolization treatment of liver-dominant metastatic leiomyosarcoma. Abdominal Radiology. https://doi.org/10.1007/s00261-025-05356-2

Vancouver

Henning J, Venkat S, Kumar P, El-Haddad G, Brohl A, Ribeiro M, et al. Drug-eluting bead transarterial chemoembolization treatment of liver-dominant metastatic leiomyosarcoma. Abdominal Radiology. 2026. doi:10.1007/s00261-025-05356-2

BibTeX
@article{Henning2026,
  author = {Henning, Jonathan and Venkat, Shree and Kumar, Premsai and El-Haddad, Ghassan and Brohl, Andrew and Ribeiro, Mauricio and Mhaskar, Rahul and Naghavi, Arash and Druta, Mihaela and Kis, Bela},
  title = {Drug-eluting bead transarterial chemoembolization treatment of liver-dominant metastatic leiomyosarcoma},
  journal = {Abdominal Radiology},
  year = {2026},
  doi = {10.1007/s00261-025-05356-2}
}
Kostenlos starten →